The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

RNA viruses frequently bypass the conventional 5′ cap‐dependent mechanism of translation by employing alternative strategies that enable them to commandeer the host’s translational machinery. A ...

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces ...

SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols ™ ExTend Cap AU ...

The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...

This article is based on a poster originally authored by Harrison H, Glen A , Andrews B, Bayle E, Duncan C, Fyfe M , Guest P, Rausch O , Swain C, Thomas B, Zemla-Brown A, Baric R, Chen Y, Froggatt H, ...

Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink’s ...

Through this agreement, Quantoom will be able to integrate TriLink’s CleanCap® mRNA capping technology into its Ntensify® platform, facilitating effective RNA synthesis and wider distribution of ...